Search company, investor...


Founded Year



Acquired | Acquired

Total Raised


About CureDM

CureDM is a biopharmaceutical company established to develop new therapies that may prevent, ameliorate or reverse diabetes and allow for the discontinuation of insulin.On February 13, 2018, CureDM was acquired by Boston Therapeutics. The terms of the transaction were not disclosed.

Headquarters Location

1201 N. Market St. Suite 701

Wilmington, Delaware, 19801,

United States


Missing: CureDM's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CureDM's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing CureDM

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CureDM is included in 2 Expert Collections, including Diabetes.



1,898 items


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CureDM Patents

CureDM has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Diabetes, Peptide hormones, Transcription factors, Syndromes, G protein coupled receptors


Application Date


Grant Date



Related Topics

Diabetes, Peptide hormones, Transcription factors, Syndromes, G protein coupled receptors



Latest CureDM News

Boston Therapeutics Announces Strategic Acquisition of CureDM

Sep 12, 2019

| Source: Boston Therapeutics, Inc. LAWRENCE, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Boston Therapeutics, Inc. (Boston Therapeutics) announces the acquisition of CureDM Group Holdings, LLC (CureDM), adding a Phase 2-ready drug to their portfolio. The CureDM islet-growing peptide, HIP2B, has demonstrated clinical efficacy for type 2 diabetes by improving first phase insulin release, increasing fasting insulin levels and insulin secretion rates. Boston Therapeutics is committed to development of treatments that impact endogenous glucose regulation. This bold move to acquire the worldwide exclusive rights to commercialize HIP2B, alongside current product offerings, is a key part of the long term plan to alleviate the health, economic and quality of life burden of diabetes. CureDM members contributed their membership interests for restricted shares of Boston Therapeutics to place their compound into the Boston Therapeutics portfolio of other technologies targeted for treatment of metabolic diseases (diabetes) and related complications. Terms include milestones and addition of a CureDM designated board member to the board of Boston Therapeutics. “We are establishing our company and its alliance partners in Asia as one that is changing the way diabetes is treated,” says Carl W. Rausch, CEO of Boston Therapeutics. He elaborates that, “Instead of a disease which you have to self-medicate for the rest of your life, we believe diabetes is a disease that can be either reversed or may be prevented entirely if you are pre-diabetic. The HIP2B peptide is a game changing compound that will fit strategically into our portfolio.” CEO of CureDM, Loraine V. Upham, notes, “We are very excited to be joining forces with Boston Therapeutics and look forward to leveraging the many synergies that exist between us to advance all products to partnering and worldwide commercialization.” Recent reporting from the American Diabetes Association celebrates strides in 2017 in diabetes management and improved outcomes that include better accessibility to continuous glucose monitors. This technology is key to enabling patients to self-monitor their response to their patient centric treatments like BTI320 and HIP2B. Management believes both treatments have the potential to change the way prediabetes and diabetes are managed and this may work independently or synergistically to improve long-term outcomes. About Boston Therapeutics, Inc. Boston Therapeutics, headquartered in Lawrence, MA (OTCQB:BTHE) is an innovator in design, development and commercialization of compounds, such as investigational BTI-320, to treat diabetes and diabetes related complications. SUGARDOWN is a registered trademark of Boston Therapeutics, Inc. About CureDM Group Holdings, LLC, CureDM Group Holdings, LLC, headquartered in Wilmington, DE with an office in Albuquerque, NM, was established in 2010 to execute clinical development of the novel peptide therapeutic, HIP2B, for the treatment of type 1 and type 2 diabetes. Forward Looking Statement This press release includes forward-looking statements. These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our limited operations and need to expand in the near future; risks associated with obtaining regulatory approval of our products; the ability to protect our intellectual property; the potential lack of market acceptance of our products; potential competition; our inability to retain key members of our management team; our inability to raise additional capital to fund our operations and business plan; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC. Boston Therapeutics expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. Boston Therapeutics, Inc.

CureDM Frequently Asked Questions (FAQ)

  • When was CureDM founded?

    CureDM was founded in 2004.

  • Where is CureDM's headquarters?

    CureDM's headquarters is located at 1201 N. Market St., Wilmington.

  • What is CureDM's latest funding round?

    CureDM's latest funding round is Acquired.

  • How much did CureDM raise?

    CureDM raised a total of $1M.

  • Who are the investors of CureDM?

    Investors of CureDM include Boston Therapeutics, Scientific Health Development and Calvert Research Institute.

  • Who are CureDM's competitors?

    Competitors of CureDM include Oligomerix, Animal Cell Therapies, NGM Biopharmaceuticals, DiaMedica, Biodel and 12 more.

Compare CureDM to Competitors

Symphony Medical

Symphony Medical is a biopharmaceutical company focused on non-destructive treatments for cardiac conduction abnormalities using cellular-based or biopolymer-based therapies.

Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform health outcomes for patients with diseases of the kidney, bone, and skin.

American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

Protemix Logo

Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.

Inflazyme Pharmaceuticals

Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.

Noveome Biotherapeutics Logo
Noveome Biotherapeutics

Noveome Biotherapeutics is regenerative medicine company focused on the research, development and clinical use of its technology platform, derived from human placental cells. This platform provides a new approach to tissue regeneration and repair in a wide range of medical conditions. Noveome's technology platform is derived from a population of cells isolated from full-term placental tissue that is normally discarded following delivery of a baby. There is no interruption in the development of the baby to procure this tissue.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.